<DOC>
	<DOCNO>NCT01816672</DOCNO>
	<brief_summary>The purpose study determine AutoloGel platelet rich plasma use non heal diabetic foot ulcer Wagner gd . 1 2 effective usual customary care</brief_summary>
	<brief_title>Efficacy AutoloGel Therapy Usual Customary Care Wagner gd 1 2 Diabetic Foot Ulcers .</brief_title>
	<detailed_description>Autologel platelet-rich plasma gel use treatment no-healing chronic wound . Prospective observational study effectiveness Autologel demonstrate promising result regard heal diabetic foot ulcer include severe Wagner grade 3 4 ulcer . The aim current trial compare efficacy , measure wound heal single-blind ( assessor ) randomize control trial , usual customary care without Autologel treat Wagner 1 2 diabetic foot ulcer .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Medicare eligible 2 . ≥18 year age 3 . Type I II diabetes require medical treatment determine physician 4 . The large nonhealing wound , multiple wound present , single wound treat ( index ulcer ) Wagner 1 2 Diabetic Foot Ulcer ( DFU ; see Appendix 9 Wagner Classification ) locate plantar , medial , lateral aspect foot ( include toe surface heel ) . Subjects heel ulcer may include another , eligible wound index ulcer 5 . For subject potentially multiple eligible DFUs , large ulcer select . There must least 4 cm index ulcer ulcer ; ulcer closer 4 cm , subject enrol ( screen failure ) 6 . Debrided ulcer size 0.5 cm2 20 cm2 7 . Demonstrated adequate offload regimen 8 . Duration ≥ 1 month first visit ( screening period ) 9 . Subject must willing comply Protocol , assess enrol clinician . 1 . Subjects know sensitive AutoloGel component ( calcium chloride , thrombin , ascorbic acid ) and/or material bovine origin 2 . Wagner 3 , 4 , 5 DFU ( see Appendix 9 Wagner Classification ) Page 15 58 3 . Any clinically infected index ulcer apparent Day 0 . The presence infection define ≥ 2 classic finding inflammation ( erythema , warmth , tenderness , pain , induration ) purulent secretion ( Lipsky , 2012 , see Appendix 4 ) 4 . Presence another wound concurrently treat might interfere index wound 5 . Ulcer DFU pathophysiology ( e.g. , venous , vasculitic , radiation , rheumatoid , collagen vascular disease , pressure , arterial etiology ) 6 . Presence underlie osteomyelitis , osteomyelitis suspect 7 . Received systemic corticosteroid immunosuppressive agent , hyperbaric oxygen therapy ( HBOT ) , electrostimulation , growth factor , cell tissuederived product wound 30 day precede screening visit ; receive radiation therapy chemotherapy within previous 6 month 8 . Any malignancy nonmelanoma skin cancer 9 . Ischemic ulcer define ankle brachial index ( ABI ; handheld Arterial Doppler ) &lt; 0.8 ( note : ABI ≥ 1 , skin perfusion pressure ( SPP ) transcutaneous oximetry ( TCOM ) must perform subject enrol ) , TCOM &lt; 30 mm Hg , SPP &lt; 30 mm Hg ; toe pressure &lt; 45 mm Hg . These measurement may concurrent initial evaluation index ulcer obtain within 90 day study enrollment do prior concurrence . 10 . Subject radiographic evidence consistent diagnosis active Charcot foot 11 . Untreated Charcot foot DFUs associate treated Charcot deformity reconstruction offload take place 12 . Ulcer expect treated advanced therapeutic ( e.g. , HBOT ) 13 . Ulcer area decrease ≥ 30 % 2week screening/runin period 14 . Subjects cognitively impair healthcare proxy 15 . Serum albumin less 2.5 g/dL 16 . Plasma Platelet count le 100 x 109/L 17 . Hemoglobin le 10.5 g/dL 18 . Subject inadequate venous access repeat blood draw require AutoloGel Administration 19 . Subject require anticipated require intervention direct improvement arterial perfusion affect area .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Wagner 1</keyword>
	<keyword>Wagner 2</keyword>
	<keyword>Non heal diabetic foot wound</keyword>
</DOC>